SU5408 is primarily used as a research compound in oncology and molecular biology studies due to its potent inhibitory effect on receptor tyrosine kinases, particularly the vascular endothelial growth factor receptor (VEGFR). It is employed to investigate angiogenesis—the formation of new blood vessels—since blocking VEGFR signaling can suppress tumor growth by cutting off blood supply to cancer cells. Researchers use SU5408 in preclinical models to evaluate anti-angiogenic strategies and to understand signaling pathways involved in cell proliferation and survival. Additionally, SU5408 serves as a tool compound for studying the role of FGF receptor (fibroblast growth factor receptor) signaling in developmental biology and disease progression. Its application helps identify potential therapeutic targets in cancers and other conditions involving abnormal cell growth or vascularization. Due to its specificity and mechanism of action, it is valuable in screening and validating new drug candidates aimed at kinase inhibition.